








Hemophilia A: Recombinant Factor VIII (rFVIII) Treatment Options

Downloaded from PersonalizeHemA.ca

rFVIII Products Available from Canadian Blood Services (2022 – 2025) ¹	ADYNOVATE® Antihemophilic Factor (Recombinant), PEGylated	ELOCTATE® (only available under selective criteria) Antihemophilic Factor (Recombinant), Fc Fusion Protein	ESPEROCT® Antihemophilic Factor (Recombinant, B-domain Truncated, PEGylated)	JIVI® (only available under selective criteria) Antihemophilic Factor (Recombinant, B-domain deleted, PEGylated)	KOVALTRY® Antihemophilic Factor (Recombinant)	XYNTHA® Antihemophilic Factor (Recombinant, B-domain deleted)	ZONOVATE® Antihemophilic Factor (Recombinant, B-domain Truncated)
Cell line	Chinese Hamster Ovary (CHO)	Human Embryonic Kidney (HEK)	Chinese Hamster Ovary (CHO)	Baby Hamster Kidney (BHK)	Baby Hamster Kidney (BHK)	Chinese Hamster Ovary (CHO)	Chinese Hamster Ovary (CHO)
On-demand	✓	✓	✓	✓	✓	✓	✓
Prophylaxis†	✓	✓	✓	✓	✓	✓	✓
Age groups	All ²	All ³	All ⁴	≥12 years of age ⁵	All ⁶	All ⁷	All ⁸
Reconstitution device	BAXJECT II Hi-Flow	PFS and Vial Adapter	PFS and Vial Adapter	PFS and Vial Adapter	PFS and Vial Adapter	PFS and Vial Adapter or Solofuse	PFS and Vial Adapter
Available sizes (250, 500, 1000, and 2000 IU)	✓ + 750, 1500, and 3000 IU	✓ + 750, 1500, and 3000 IU	✓ + 500, 1000, 1500, 2000, and 3000 IU	✓ + 3000 IU	✓ + 3000 IU	✓ + 3000 IU	✓ + 3000 IU
Diluent volume	 2 or 5 mL (depending on vial)	 3 mL	 4 mL	 2.5 mL	 2.5 or 5 mL (depending on vial)	 4 mL	 4 mL
rFVIII modification	PEGylation	Fc Fusion	PEGylation	PEGylation	No Fusion or PEGylation	No Fusion or PEGylation	No Fusion or PEGylation
Contains non-medicinal polysorbate or poloxamer (types of PEG)	✓ (PS80)	✓ (PS80)	✓ (PS80)	✓ (PS80)	✓ (PS80)	✓ (PS80)	✓ (PS80)

The comparative information provided in the table above does not convey the relative effectiveness and/or safety of the listed products. As with all treatment options, your licensed healthcare professional must determine what therapy is appropriate for you based on their assessment of your individual treatment needs and goals.

† Prophylaxis is a course of treatment to prevent bleeds.

IU = international units; PFS = pre-filled syringe; PS80 = polysorbate 80

1. Available from: <https://chscontact.ca/cbs-announces-fviii-and-fix-products-for-2022-2025/>

2. Adynovate [Product Monograph](#). Takeda Canada Inc. November 5, 2021.

3. Eloctate [Product Monograph](#). Bioerativ Canada Inc. November 8, 2021.

4. Esperoct [Product Monograph](#). Novo Nordisk Canada Inc. May 6, 2020.

5. JIVI [Product Monograph](#). Bayer Inc. October 18, 2018.

6. Kovaltry [Product Monograph](#). Bayer Inc. June 28, 2019.

7. Xyntha [Product Monograph](#). Pfizer Canada Inc. May 11, 2016.

8. Zonovate [Product Monograph](#). Novo Nordisk Canada Inc. April 12, 2021.

ADYNOVATE is a trademark or registered trademark of Baxalta Incorporated.

ELOCTATE is a trademark or registered trademark of Bioerativ Therapeutics Inc., an affiliate of Sanofi.

ESPEROCT is a registered trademark of Novo Nordisk Health Care AG and is used under license by Novo Nordisk Canada Inc.

JIVI is a registered trademark of Bayer Inc.

KOVALTRY is a registered trademark of Bayer Inc.

XYNTHA is a registered trademark of Wyeth LLC, owner/Pfizer Canada Inc., Licensee.

ZONOVATE is a registered trademark of Novo Nordisk Health Care AG and is used under license by Novo Nordisk Canada Inc.

Takeda Canada Inc.
www.takeda.com/en-ca

TAKEDA™ and the TAKEDA Logo® are trademarks of Takeda Pharmaceutical Company Limited, used under license.

© 2022 Takeda Pharmaceutical Company Limited. All rights reserved.

